Tiespectus Improves Vision and Retinal Thickness in BRVO

Part one of the RIOJA trial reports no serious adverse events or dose-limiting toxicity.

By: Jim Gallagher, senior managing editor

Retinal Physician October 19, 2025

5 Key Takeaways

1

Tiespectus demonstrated a mean gain of 16.7 letters in best-corrected visual acuity in patients with BRVO after 12 weeks.
2

The phase 1/2a RIOJA trial showed a mean central subfield thickness reduction of 157.8 µm following treatment with Tiespectus.
3

No serious ocular or systemic adverse events or dose-limiting toxicity were reported during the RIOJA trial.
4

The trial enrolled 12 treatment-naïve patients who received 3 monthly intravitreal injections of Tiespectus.
5

Tiespectus is a bispecific antibody that activates Tie2 and inhibits VEGF to stabilize retinal blood vessels and reduce macular fluid.

Jim Gallagher

Senior Managing Editor

Affiliations: Glaucoma Physician

Specialties: Ophthalmology

Bio: Jim Gallagher is Senior Managing Editor of Glaucoma Physician, a publication dedicated to developments in glaucoma diagnosis, treatment, and patient care. In his editorial role he writes, curates, and oversees content spanning clinical updates, conference coverage, and emerging innovations in glaucoma science and care. Though not a clinician himself, Gallagher plays a pivotal role in translating complex ophthalmologic research and practice trends to an audience of glaucoma specialists, contributing features, editorials, and news reporting. He frequently collaborates with glaucoma physicians, researchers, and thought leaders to highlight advances in therapies, surgical devices, and care delivery.

PentaVision

Retinal Physician

Tiespectus Improves Vision and Retinal Thickness in BRVO

5 Key Takeaways

1

2

3

4

5

Recommendations